Bengal Physician Journal

Register      Login

VOLUME 9 , ISSUE 1 ( January-April, 2022 ) > List of Articles


Necessity of Baseline Diabetic Autonomic Neuropathy Screening to Start Cardiovascular Safety Outcome Trials: A Focus on Antidiabetic Agents and Autonomic Neurointegrity

Shambo S Samajdar, Shashank Joshi, Santanu Kumar Tripathi

Keywords : Antidiabetic agents, Cardiovascular outcome trials, Cardiovascular risk factors, Diabetic autonomic neuropathy

Citation Information : Samajdar SS, Joshi S, Tripathi SK. Necessity of Baseline Diabetic Autonomic Neuropathy Screening to Start Cardiovascular Safety Outcome Trials: A Focus on Antidiabetic Agents and Autonomic Neurointegrity. Bengal Physician Journal 2022; 9 (1):9-12.

DOI: 10.5005/jp-journals-10070-7069

License: CC BY-NC 4.0

Published Online: 01-04-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Diabetic autonomic neuropathy (DAN) is an individual risk factor for nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, other major cardiovascular events like hospitalization for angina, hospitalization for heart failure, urgent revascularization for unstable angina, and death from any cause. Diabetic autonomic neuropathy screening is of paramount importance for cardiovascular risk stratification in patients with and without cardiovascular disease; as a marker for patients requiring more intensive monitoring during the perioperative period and other physiological stresses; and as an indicator for more intensive pharmacotherapeutic and lifestyle management of comorbid conditions. The present review highlights the necessity of DAN screening in starting cardiovascular outcome trials for antidiabetic agents.

  1. Rebrina SV, Barada A, Duvnjak LS. Diabetic Autonomic Neuropathy. Diabetologia Croatica 2013;42(3):73–79.
  2. Serhiyenko VA, Serhiyenko AA. Cardiac Autonomic Neuropathy: Risk Factors, Diagnosis and Treatment. World J Diabet 2018;9(1):1–24. DOI: 10.4239/wjd.v9.i1.1.
  3. Vinik AI, Erbas T, Casellini CM. Diabetic Cardiac Autonomic Neuropathy, Inflammation and Cardiovascular Disease. J Diabet Investigat 2013;4(1):4–18. DOI: 10.1111/jdi.12042.
  4. Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabet Care 2010;33(10):2285–2293. DOI: 10.2337/dc10-1303.
  5. Wackers FJ, Young LH, Inzucchi SE, et al. Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects: The DIAD Study. Diabet Care 2004;27:1954–1961. DOI: 10.2337/diacare.27.8.1954.
  6. Kempler P, Tesfaye S, Chaturvedi N, et al., the EURODIAB IDDM Complications Study Group. Autonomic Neuropathy is Associated with Increased Cardiovascular Risk Factors: The EURODIAB IDDM Complications Study. Diabet Med 2001;19:900–909. DOI: 10.1046/j.1464-5491.2002.00821.x.
  7. Pop-Busui R, Evans GW, Gerstein HC, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010;33(7):1578–1584. DOI: 10.2337/dc10-0125.
  8. Marso SP, McGuire DK, Zinman B, et al. Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events)–DEVOTE 1. Am Heart J 2016;179:175–183. DOI: 10.1016/j.ahj.2016.06.004.
  9. US Food and Drug Administration Guidance for industry: Diabetes mellitus—Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available from:
  10. Hirshberg B, Raz I. Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs. Diabet Care 2011;34:S101–S106. DOI: 10.2337/dc11-s202.
  11. John M, Unnikrishnan AG, Kalra S, et al. Cardiovascular Outcome Trials for Anti-Diabetes Medication: A Holy Grail of Drug Development? Ind Heart J 2016;68(4): 564–571. DOI: 10.1016/j.ihj.2016.02.017.
  12. Schnell O, Rydén L, Standl E, et al; D&CVD EASD Study Group. Updates on cardiovascular outcome trials in diabetes [published correction appears in Cardiovasc Diabetol 2017 Nov 15;16(1):150]. Cardiovasc Diabetol 2017;16(1):128. DOI: 10.1186/s12933-017-0610-y.
  13. Maser RE, Mitchell BD, Vinik AI, et al. The Association between Cardiovascular Autonomic Neuropathy and Mortality in Individuals with Diabetes: A Meta-Analysis. Diabet Care 2003;26:1895–1901. DOI: 10.2337/diacare.26.6.1895.
  14. Williams S, Abbott D, Morfis L, et al. Effects of Glibenclamide on Blood Pressure and Cardiovascular Responsiveness in Non-Insulin Dependent Diabetes Mellitus. J Hypertens 1998;16:705–711. DOI: 10.1097/00004872-199816050-00019.
  15. Wulffelé MG, Kooy A, de Zeeuw D, et al. The Effect of Metformin on Blood Pressure, Plasma Cholesterol and Triglycerides in Type 2 Diabetes Mellitus: A Systematic Review. J Intern Med 2004;256:1–14. DOI: 10.1111/j.1365-2796.2004.01328.x.
  16. Kobayashi D, Takamura M, Murai H, et al. Effect of Pioglitazone on Muscle Sympathetic Nerve Activity in Type 2 Diabetes Mellitus with α-Glucosidase Inhibitor. Auton Neurosci 2010;158:86–91. DOI: 10.1016/j.autneu.2010.05.003.
  17. Gill A, Hoogwerf BJ, Burger J, et al. Effect of Exenatide on Heart Rate and Blood Pressure in Subjects with Type 2 Diabetes Mellitus: A Double-Blind, Placebo-Controlled, Randomized Pilot Study. Cardiovasc Diabetol 2010;9:6. DOI: 10.1186/1475-2840-9-6.
  18. Nakatani Y, Kawabe A, Matsumura M, et al. Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability. Diabet Care 2016;39:e22–e23. DOI: 10.2337/dc15-1437.
  19. Guyenet PG. Putative Mechanism of Salt-dependent Neurogenic Hypertension: Cell-Autonomous Activation of Organum Vasculosum Laminae Terminalis Neurons by Hypernatremia. Hypertension 2017;69:20–22. DOI: 10.1161/HYPERTENSIONAHA.116.08470.
  20. Anderson EA, Hoffman RP, Balon TW, et al. Hyperinsulinemia Produces both Sympathetic Neural Activation and Vasodilation in Normal Humans. J Clin Invest 1991;87:2246–2252. DOI: 10.1172/JCI115260.
  21. Samajdar SS, Mukherjee S, Tripathi SK, et al. Early Initiation of Insulin Therapy in Newly Diagnosed Patients with Type 2 Diabetes and Exploring the Legacy Effect—A Single-arm Prospective Observational Study. Bengal Phys J 2020;7(3):52–54. DOI: 10.5005/jp-journals-10070-7031.
  22. Samajdar SS, Mukherjee S, Joshi S, et al. Cardiovascular Outcome Trials in Indian Perspective: A Call to Indian Drug Regulators. J Indian Med Assoc 2020;118(6):70–72.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.